Risk factors

OnKure Therapeutics (OKUR) risk factors

Item 1A of every OnKure Therapeutics, Inc. 10-K on file, and what changed from one year to the next.

Open OKUR in Gloomberb →
  • FY2025 10-K risk factors

    77 risks, 6 new, 8 dropped, 11 reworded since the prior year. Capital runway extends only into the fourth quarter of 2026, creating going concern doubt. Reliance centers on advancing product candidate OKI-219 through Phase 1 trials.

    Filed Mar 12, 2026
  • FY2024 10-K risk factors

    79 risks. Clinical-stage biopharmaceutical company with no approved products, relying primarily on lead candidate OKI-219 in Phase 1 trials.

    Filed Mar 10, 2025